Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was one of the few companies that continued to operate as usual in 2020 despite the coronavirus pandemic situation, severely impacting many industries.
The company generated an impressive $4.5 billion revenue in 4Q2020 and $16.7 billion during the entire year. The impressive performance was largely fueled by global demand for essential medicines. Essential product and services providers such as Teva were allowed to continue operating with the right measures in place during the pandemic, allowing the biopharma to avoid disruptions to product launches, R&D, and supply chain activity.
"Following a strong fourth quarter performance, we have met all components of our 2020 financial guidance," stated Teva CEO Kåre Schultz.
The CEO also noted that Teva’s main growth drivers, such as AJOVY and AUSTEDO, achieved important milestones and achieved impressive results. The company’s generics business also yielded a strong performance in 2020, particularly thanks to the rollout of generic versions of Atripla and Truvada, which are HIV treatments sold in the U.S. The biosimilar commercialization agreement allowed Teva to boost its biopharmaceutical pipeline.
Teva’s performance outlook
The pharmaceutical giant targets perpetual strong results well into the future, and it is currently laying down the foundation for that success through the advancement of pipeline products. Teva is optimistic about risperidone, which it has been developing as a schizophrenia drug delivered through injections. The drug’s phase 3 trial yielded positive results.
Teva expects its 2021 revenue to range between $16.4 and $16.8 billion. Some of the other measures that the company is taking to achieve its revenue objectives include signing a biosimilar commercialization agreement that will boost its biopharmaceutical lineup. Teva’s strategy for 2021 will double down on portfolio and manufacturing network and optimization. Cost optimization will also play an important role in the company’s profitability.
R&D investments are a key part of Teva’s operations to create new products, especially those that target common health conditions. The company continues to focus on this area to develop more products that will contribute to higher revenues and profitability in the future.